Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01482949 · ClinicalTrials.gov registry record · Phase 2
A Rollover Protocol for Subjects Previously Treated With AGS-003
A Phase 2 study, sponsored by Argos Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01482949: Clinical Trial Phase 2 study, sponsored by Argos Therapeutics.
NCT01482949 is a Phase 2 study that was terminated before completion, run by Argos Therapeutics. The registered enrollment target is 2 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01482949, a Phase 2 study, was terminated before completion, sponsored by Argos Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate clinical response to AGS-003 alone or in combination with sunitinib therapy.
Primary Outcome
Clinical antitumor activity of AGS-003 will be assessed as an objective tumor response by Response Evaluation Criteria in Solid Tumors (RECIST).
Interventions
- DRUG AGS-003
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2011-09 |
| Est. Completion | 2018-05 |
| Phase | Phase 2 |
Why NCT01482949 stopped before completion
NCT01482949 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which AGS-003 is the first listed.
NCT01482949 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01482949 about?
NCT01482949 is a clinical study titled "A Rollover Protocol for Subjects Previously Treated With AGS-003". The purpose of this study is to evaluate clinical response to AGS-003 alone or in combination with sunitinib therapy.
What is the current status of trial NCT01482949?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2011-09. Estimated completion is 2018-05.
What interventions are being tested in trial NCT01482949?
The interventions under investigation include: AGS-003 (DRUG).
Who is sponsoring clinical trial NCT01482949?
This trial is sponsored by Argos Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01482949's enrollment target sits among peer trials
2 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia